Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 281 0850

Website: kodiak.com

Address:

1200 Page Mill Road, Palo Alto, United States

Stekli27 Mar. 19 at 12:18 PM

$KOD when do we get the results of glow 2? 26th?

1 · Reply

Stekli27 Mar. 17 at 9:11 PM

$KOD 👀

0 · Reply

Cutlass Mar. 17 at 7:42 PM

$KOD Late volume coming in ✍️

0 · Reply

RandomInvestor777 Mar. 17 at 3:31 PM

$KOD IMO Glow 2 hit - 70%/100% 38-46$ Glow 2 fail (safety issues)- -30%/-40% 13-16$

1 · Reply

aletz Mar. 13 at 10:18 AM

$KOD https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk3/ #4 pick from March Week 3 AI scanner. Visit the link for more ideas.

0 · Reply

Stekli27 Mar. 10 at 1:37 PM

$KOD Again perky 🥳

0 · Reply

Stekli27 Mar. 6 at 9:27 PM

$KOD In a report released today, from LifeSci Capital assigned a Buy rating to Kodiak Sciences, with a price target of $40.00. Dolezal is a 5-star analyst with an average return of 17.3% and a 45.4% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Rocket Pharmaceuticals, and Oculis Holding.

0 · Reply

RandomInvestor777 Mar. 6 at 2:51 AM

$KOD AH PR tomorrow for monday results?

1 · Reply

Stekli27 Mar. 4 at 10:14 PM

$NRSN $KOD After one year still invested in both. They both have a huge binary month ahead and news could drop any day now. $KOD – GLOW2 readout $NRSN – Phase 3 financing + AD data release This is exactly why we invest in these names. High risk, but potentially huge upside. Chances: KOD ~65%, NRSN ~35% (without major dilution). Let’s see what March brings. GL to all holders.

2 · Reply

Benalish Mar. 4 at 1:59 PM

$QURE They took $KOD to cash, then it bounced back to about 15x cash. That is what QURE is doing right now; they have already taken it down to below its cash level at $9 per share. Now, once it becomes clear that Makary is going to have to make some adjustments (just like he did with $MRNA on their vaccine) it's going to bounce back to $25. MACO! GLTA!

2 · Reply

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Jan 22, 2026, 10:26 AM EST - 2 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX LITE

Jan 12, 2026, 8:45 PM EST - 2 months ago

Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 8:19 PM EST - 2 months ago

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:26 PM EST - 3 months ago

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 16, 2025, 10:55 PM EST - 3 months ago

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 3 months ago

Kodiak Sciences Announces Proposed Public Offering of Common Stock

Nov 13, 2025, 4:05 PM EST - 4 months ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 12, 2025, 5:48 PM EST - 4 months ago

Kodiak Sciences to Present at Upcoming Investor Conferences

Nov 5, 2025, 7:00 AM EST - 4 months ago

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

Oct 31, 2025, 12:01 PM EDT - 4 months ago

The Big 3: GOOGL, KOD, FTK

GOOG GOOGL FTK

Sep 15, 2025, 7:00 AM EDT - 6 months ago

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Sep 2, 2025, 8:00 AM EDT - 7 months ago

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Aug 27, 2025, 10:40 AM EDT - 7 months ago

Harbour BioMed Reports 2025 Interim Results

Aug 27, 2025, 6:54 AM EDT - 7 months ago

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

Aug 19, 2025, 2:18 PM EDT - 7 months ago

Kodiak Sciences to Present at American Chemical Society Fall 2025

Aug 13, 2025, 4:00 PM EDT - 7 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 9 months ago

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Jun 25, 2025, 4:45 PM EDT - 9 months ago

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

May 29, 2025, 9:32 PM EDT - 10 months ago

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 14, 2025, 4:15 PM EDT - 11 months ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 1, 2025, 11:43 PM EDT - 11 months ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:39 PM EDT - 1 year ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Feb 23, 2025, 8:08 PM EST - 1 year ago

Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders

Feb 4, 2025, 7:30 AM EST - 1 year ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Jan 7, 2025, 6:00 AM EST - 1 year ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:33 PM EST - 1 year ago

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Nov 14, 2024, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 11, 2024, 6:15 AM EST - 1 year ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 1 year ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

May 29, 2024, 4:36 PM EDT - 1 year ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 2 years ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Mar 28, 2024, 8:57 PM EDT - 2 years ago

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 6:30 AM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 2 years ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 6, 2023, 5:00 AM EST - 2 years ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 1, 2023, 11:21 PM EDT - 2 years ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Sep 8, 2023, 6:00 AM EDT - 2 years ago

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 7, 2023, 6:00 AM EDT - 2 years ago

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Stekli27 Mar. 19 at 12:18 PM

$KOD when do we get the results of glow 2? 26th?

1 · Reply

Stekli27 Mar. 17 at 9:11 PM

$KOD 👀

0 · Reply

Cutlass Mar. 17 at 7:42 PM

$KOD Late volume coming in ✍️

0 · Reply

RandomInvestor777 Mar. 17 at 3:31 PM

$KOD IMO Glow 2 hit - 70%/100% 38-46$ Glow 2 fail (safety issues)- -30%/-40% 13-16$

1 · Reply

aletz Mar. 13 at 10:18 AM

$KOD https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk3/ #4 pick from March Week 3 AI scanner. Visit the link for more ideas.

0 · Reply

Stekli27 Mar. 10 at 1:37 PM

$KOD Again perky 🥳

0 · Reply

Stekli27 Mar. 6 at 9:27 PM

0 · Reply

RandomInvestor777 Mar. 6 at 2:51 AM

$KOD AH PR tomorrow for monday results?

1 · Reply

Stekli27 Mar. 4 at 10:14 PM

2 · Reply

Benalish Mar. 4 at 1:59 PM

2 · Reply

Quantumup Mar. 2 at 9:16 PM

Clear Street⬆️ $OCUL to $28/reiterated at Buy, plus⬆️LoS to 65%. $EYPT $REGN RHHBY $KOD $SRZN Here's what Clear Street said: https://x.com/Quantumup1/status/2028579385851187401?s=20

0 · Reply

StockMomentumLab Mar. 2 at 6:11 PM

$OCUL William Blair reiterates Outperform following positive SOL-1 top-line data for Axpaxli in wet AMD. 👉Click to view @StockMomentumLab for timely updates amid the volatility. Takeaways: • SOL-1 supports durability + efficacy profile • SOL-R readout expected Q1 2027 • Company planning near-term NDA submission • HELIOS-3 launch signals pipeline expansion Blair sees potential for Axpaxli to be a meaningful advance in nAMD, with possible blockbuster upside if data continues to deliver. Eyes now on regulatory path + SOL-R execution. $EYPT $REGN Roche Holding $SRZN $KOD

2 · Reply

Quantumup Mar. 2 at 5:06 PM

William Blair reiterated $OCUL at an Outperform rating. $EYPT $REGN RHHBY $SRZN $KOD Here's what William Blair had to say: https://x.com/Quantumup1/status/2028516173059690609?s=20

0 · Reply

rlichgolf Mar. 1 at 7:35 PM

$KOD baker bros added another 2.5 million shares ahead of upcoming data releases. They seem to be pretty confident

0 · Reply

OfficialStocktwitsUser Feb. 25 at 11:11 PM

$KOD RSI: 66.29, MACD: 0.3823 Vol: 2.00, MA20: 24.25, MA50: 25.82 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

spinusn27 Feb. 25 at 1:29 PM

$KOD lots of bouncing this morning in pre market. Good luck today!!!

0 · Reply

Snackdaddy Feb. 24 at 10:17 PM

$KOD March is the month. good sign is it is looking to test thehigh ofnChristmas Eve. I feel like a run up and news sell off might be what happens. Profits secured then a reinvestment ifthe news is good as KOD will be a new company not wildly volatile and safe long play

0 · Reply

belugatrade Feb. 24 at 9:46 PM

$KOD at $28. wanting to break out badly.

0 · Reply

Ecolispewy Feb. 24 at 8:38 PM

$KOD Spread tightening

0 · Reply

spinusn27 Feb. 24 at 4:16 PM

$KOD question is what are the shorts going to do? That 28.50 break has to be making them nervous.

0 · Reply

Stekli27 Feb. 24 at 4:12 PM

$KOD so close 💖

0 · Reply

Cutlass Feb. 24 at 4:11 PM

$KOD So Perky 🙆‍♀️

0 · Reply

Market Cap	1.27B
Revenue (ttm)	0.00
Net Income (ttm)	-176.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	708,100
Avg Vol	651,302
Day's Range	N/A - N/A
Shares Out	53.05M
Stochastic %K	22%
Beta	2.61
Analysts	Sell
Price Target	$32.86